Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2019

Source: https://www.researchbymarkets.com/report/coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2019-268219.html

For queries regarding this report: https://www.researchbymarkets.com/sample-request/268219

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutic Products under Development, Key Players in Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Overview, Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline, Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Assessment

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2019

Summary

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2019, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can’t get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts’ blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 13, 6, 3, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Ascendia Pharmaceuticals LLC
AstraZeneca Plc
Athera Biotechnologies AB
Bayer AG
Cadrock Pty Ltd
Capricor Therapeutics Inc
CardioVascular BioTherapeutics Inc
Chong Kun Dang Pharmaceutical Corp
CSL Ltd
Cynata Therapeutics Ltd
DalCor Pharmaceuticals Inc
Gilead Sciences Inc
Hemostemix Inc
Human Stem Cells Institute
Idorsia Pharmaceutical Ltd
Kowa Co Ltd
LipimetiX Development Inc
Livzon Pharmaceutical Group Co Ltd
MedImmune LLC
Orion Corp
Proteon Therapeutics Inc
Resverlogix Corp
Reven Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
The Medicines Company
Verseon Corp
VESSL Therapeutics Ltd
ViroMed Co Ltd
Virtual Drug Development Inc
XyloCor Therapeutics Inc

Contact Us:

ResearchByMarkets.com

Ritesh Tiwari, Director

enquiry@researchbymarkets.com

USA: +1-800-416-3124

https://www.researchbymarkets.com/aboutus

Follow us on Social Media:

Facebook: https://www.facebook.com/researchbymarkets/

LinkedIn: https://www.linkedin.com/company/researchbymarkets/

Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.